In this double blinded trial, the participants, age 50-75 years, will be randomized to receive 0, 225, 400, or 650 mg daily for 12 weeks and will be tested before and after the intervention. Cognitive testing will be conducted prior to randomization, and at weeks 4, 12, and 20 of the study.